Grail, Inc. · NASDAQ:GRAL

Grail — ERS International Congress 2022

13 slides from Grail's conference presentation, September 2022

  1. Slide 1: Prevalence and demographics of marijuana users in a Lung Cancer Screening cohort

    Prevalence and demographics of marijuana users in a Lung Cancer Screening cohort A. Bhamani, J. L. Dic kson, C. Horst, S. Tisi, H. Hall, A. Creamer, R. Prendec ki, J. Mccabe, S. L. Quaife, F. Bojang, D. Arancon, K. Gyer tson, A. M. Mullin, J. Teague, L. Farrelly, A. Hac kshaw, S. M. Janes

  2. Slide 2: Conflict of interest disclosure

    Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: Affiliation / Financial interest Commercial company Grants/research support: The SUMMIT Study is funded by GRAIL LLC through a research grant awarded to SMJ as Principal Inv

  3. Slide 3: Aims / Learning objectives

    Aims / Learning objectives 1. To determine the proportion of individuals in a Lung Cancer Screening (LCS) cohort who report a regular marijuana smoking history 2. To determine the number of current, regular marijuana smokers in this cohort 3. To assess the demographics of regular marijuana users in

  4. Slide 4: Background

    Background • Marijuana is the most widely used illicit drug in the world • The prevalence of marijuana use in older populations is on the rise • According to survey in USA, the past-year prevalence of marijuana use among those ≥ 50 years old increased by 71.4% from 2006 to 2013 (Han et al., 2017) •

  5. Slide 5: Relevance to Lung Cancer Screening

    Relevance to Lung Cancer Screening • Current risk assessment criteria for inclusion in Lung Cancer Screening (LCS) programmes are based on a history of cigarette smoking • History of marijuana use is not considered • Marijuana smokers with no significant history of cigarette use may, therefore, be e

  6. Slide 6: Methods

    Methods • The SUMMIT Study [NCT03934866] is a prospective observational cohort study which aims to assess the implementation of Low Dose Computed Tomography (LDCT) scanning for LCS in a high-risk population and validate a multi-cancer early detection blood test. • 55-77 year olds with documented smo

  7. Slide 7: Methods

    Methods • Individuals attending LHC also asked if they had ever smoked products other than cigarettes, including marijuana • A history of regular marijuana use was defined as having ever smoked marijuana at least once a week for at least one year • Those self reporting a regular marijuana smoking hi

  8. Slide 8: Prevalence of marijuana use amongst study participants

    Prevalence of marijuana use amongst study participants All SUMMIT participants (n=13,035) Ever used marijuana (n=2,135/ 16.4%) Ever used marijuana regularly (n=824/ 6.3%) Used marijuana regularly into 50s (n=559/ 4.3%) Current, regular marijuana users (n=357/ 2.7%)

  9. Slide 9: Comparison with rest of cohort

    Comparison with rest of cohort Current or former regular All other study participants p-value marijuana users (n=824) (n=12,211) Mean age 63.15 (SD = 5.403) 65.54 (SD = 6.119) <0.001 Gender Male 613 (74.4%) 6878 (56.3%) <0.001 Female 211 (25.6%) 5333 (43.7%) Smoking status Current 471 (57.2%) 5,905

  10. Slide 10: Conclusion

    Conclusion • 6.3% of participants reported a history of regular marijuana use • Compared to entire study cohort, they were more likely to be males, current cigarette smokers and have higher education degrees • Analysis ongoing to assess prevalence of airflow obstruction and emphysema amongst regular

  11. Slide 11: List of references

    List of references • World Health Organisation. Alcohol, Drugs and Addictive Behaviours Unit. https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive- behaviours/drugs-psychoactive/cannabis. • Fligiel SE, Roth MD, Kleerup EC et al. Tracheobronchial histopathology in hab

  12. Slide 12: Acknowledgements

    Acknowledgements • SUMMIT Study team • Summit Study participants • GRAIL LLC • University College London Hospitals NHS Foundation Trust • UCL Cancer Trials Centre

  13. Slide 13: International Congress 2022 Barcelona

    INTERNATIONAL CONGRESS 2022 BARCELONA Spain, 4-6 September

Grail — ERS International Congress 2022 on 6ix